Literature DB >> 21376797

Human papillomavirus vaccine uptake and barriers: association with perceived risk, actual risk and race/ethnicity among female students at a New York State university, 2010.

Robert A Bednarczyk1, Guthrie S Birkhead, Dale L Morse, Helene Doleyres, Louise-Anne McNutt.   

Abstract

Understanding human papillomavirus (HPV) vaccine uptake patterns is critical to improve vaccination levels. Approximately half (56%) of female undergraduate students surveyed at a large public university reported HPV vaccine series initiation, with 79% of initiators completing the three dose series. Predictors of series initiation included having a conversation with a health-care provider about the vaccine, reporting a history of sexual intercourse and receipt of the meningitis vaccine. Compared to whites, black/African-American women were 33% less likely to have initiated HPV vaccination. Common reasons for not receiving the HPV vaccine included concerns about vaccine safety and doctors' not recommending vaccination.
Copyright © 2011 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21376797     DOI: 10.1016/j.vaccine.2011.02.045

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  39 in total

1.  Prevalence and predictors of human papillomavirus (HPV) vaccination among young women surviving childhood cancer.

Authors:  James L Klosky; Brianne Favaro; Kelly R Peck; Jessica L Simmons; Kathryn M Russell; Daniel M Green; Melissa M Hudson
Journal:  J Cancer Surviv       Date:  2015-11-16       Impact factor: 4.442

2.  Racial disparities in human papillomavirus vaccination: does access matter?

Authors:  Amanda Gelman; Elizabeth Miller; Eleanor Bimla Schwarz; Aletha Y Akers; Kwonho Jeong; Sonya Borrero
Journal:  J Adolesc Health       Date:  2013-08-27       Impact factor: 5.012

3.  Incidence of sexually transmitted infections after human papillomavirus vaccination among adolescent females.

Authors:  Anupam B Jena; Dana P Goldman; Seth A Seabury
Journal:  JAMA Intern Med       Date:  2015-04       Impact factor: 21.873

Review 4.  Addressing HPV vaccine myths: practical information for healthcare providers.

Authors:  Robert A Bednarczyk
Journal:  Hum Vaccin Immunother       Date:  2019-02-20       Impact factor: 3.452

5.  Parental Choice of Recall Method for HPV Vaccination: A Pragmatic Trial.

Authors:  Allison Kempe; Sean T O'Leary; Jo Ann Shoup; Shannon Stokley; Steven Lockhart; Anna Furniss; L Miriam Dickinson; Juliana Barnard; Matthew F Daley
Journal:  Pediatrics       Date:  2016-02-26       Impact factor: 7.124

6.  Vaccination and 30-Day Mortality Risk in Children, Adolescents, and Young Adults.

Authors:  Natalie L McCarthy; Julianne Gee; Lakshmi Sukumaran; Eric Weintraub; Jonathan Duffy; Elyse O Kharbanda; Roger Baxter; Stephanie Irving; Jennifer King; Matthew F Daley; Rulin Hechter; Michael M McNeil
Journal:  Pediatrics       Date:  2016-02-01       Impact factor: 7.124

7.  Binge drinking, HIV/HPV co-infection risk, and HIV testing: Factors associated with HPV vaccination among young adults in the United States.

Authors:  O O Olusanya; L T Wigfall; M E Rossheim; A Tomar; A E Barry
Journal:  Prev Med       Date:  2020-02-28       Impact factor: 4.018

8.  Emergency medicine physician attitudes toward HPV vaccine uptake in an emergency department setting.

Authors:  Mandy Hill; Glory Okugo
Journal:  Hum Vaccin Immunother       Date:  2014-10-30       Impact factor: 3.452

9.  Human papillomavirus vaccine initiation and awareness: U.S. young men in the 2010 National Health Interview Survey.

Authors:  Peng-Jun Lu; Walter W Williams; Jun Li; Christina Dorell; David Yankey; Deanna Kepka; Eileen F Dunne
Journal:  Am J Prev Med       Date:  2013-04       Impact factor: 5.043

10.  Human Papillomavirus Vaccination and Age at First Sexual Activity, National Health and Nutrition Examination Survey.

Authors:  Emiko Y Petrosky; Gui Liu; Susan Hariri; Lauri E Markowitz
Journal:  Clin Pediatr (Phila)       Date:  2016-10-01       Impact factor: 1.168

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.